William G. Gerber

diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.

Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA.

Galileo Pharmaceuticals, Inc. develops therapeutics and pharmaceuticals for redox failure such as stroke, heart attack, and diabetes. It also owns and operates laboratories. The company was founded by Dr. Guy Miller in 1998 and is headquartered in Santa Clara, CA.

Vivaldi Biosciences Inc. develops and markets vaccines. It specializes in developing live attenuated influenza vaccines (LAIVs). The company was founded by Eliott Kieff, Peter Palese, and Adolfo García-Sastre in 2006 and is headquartered in Fort Collins, CO.

Nexus Dx, Inc. engages in the provision of of a near patient testing system and advanced diagnostic solution. Its offers point-of-care (POC) immunoassay, IB10 analyzer system, and tests for established critical care parameters. The company was founded on January 16, 2009 and is headquartered in San Diego, CA.

ITC Nexus Holding Co., Inc. is a hospital-focused point-of-care (POC) cardiovascular diagnostics company. It is primarily focused on the manufacture and sale of testing equipment and associated disposables used to measure blood coagulation and platelet response. The company’s two lead products are the Hemochron and VerifyNow systems. Hemochron is used by physicians during cardiovascular interventions to monitor a patient’s blood clotting factors. VerifyNow is used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.

NABsys, Inc. developed DNA analysis sequencing platform. Its platform used solid-state nanodetectors to analyze single DNA molecules, revealing both location and identity of DNA sequences over long distances. The firm system was designed to set new standards for accuracy, speed and scalability, offering compelling advantages for the analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. The company was founded by Xinsheng Sean Ling, Leon N. Cooper and Barrett Bready in 2004 and was headquartered in Providence, RI.

Fabric Genomics, Inc. operates as an analytical genome interpretation company. It develops scalable and fully integrated informatics systems specifically design to interpret human genome sequences for research and clinical applications. The company was founded by by Martin G. Reese, Edward S. Kiruluta, John Stuelpnagel, and Paul Billings and is headquartered in Oakland, CA.

SynGen, Inc. designs and manufactures innovative devices designed for separation and isolation of therapeutic cells. It offers products that improve the recovery, purity and viability of stem and other clinically important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture. The firms products include SynGenX-1000 System, CryoPRO-2 Bag Sets, SynGenX-LAB System, and tube welding workstation. The company was founded by Philip H. Coelho, Gabriel G. Alvarado, and George J. Barry in 1999 and is headquartered in Rancho Cordova, CA

Part of Bayer AG, Chiron Diagnostics Corp. is a company that develops medical diagnostic products. The company is based in East Walpole, MA. Chiron Diagnostics was acquired by Bayer AG from Chiron Corp. on November 30, 1998 for $1,100 million.